Cost Calculation for a Flash Glucose Monitoring System for Adults With Type 2 Diabetes Mellitus Using Intensive Insulin – a UK Perspective
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: Estimate the costs associated with flash glucose monitoring as a replacement for routine self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus (T2DM) using intensive insulin, from a UK National Health Service (NHS) perspective. Methods: The base-case cost calculation used the frequency of SMBG and healthcare resource use observed in the REPLACE trial. Scenario analyses considered SMBG at the flash monitoring frequencies observed in the REPLACE trial (8.3 tests per day) and a real-world analysis (16 tests per day). Results: Compared with 3 SMBG tests per day, flash monitoring would cost an additional £585 per patient per year, offset by a £776 reduction in healthcare resource use, based on reductions in emergency room visits (41%), ambulance call-outs (66%) and hospital admissions (77%) observed in the REPLACE trial. Per patient, the estimated total annual cost for flash monitoring was £191 (13.4%) lower than for SMBG. In the scenarios based on acquisition cost alone, flash monitoring was cost-neutral versus 8.3 SMBG tests per day (5% decrease) and cost-saving at higher testing frequencies. Conclusion: From a UK NHS perspective, for patients with T2DM using intensive insulin, flash monitoring is potentially cost-saving compared with routine SMBG irrespective of testing frequency. Keywords
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“In addition to these considerations, it is possible the reduction in hypoglycaemia observed in the REPLACE trial in favour of flash monitoring(23) may lead to longer-term reductions in cardiovascular disease.(44,45) Potentially, this could reduce the overall costs of the flash monitoring system over the longer term.”
BackgroundRisk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 9×
“(2017) suggested that older patients using flash monitoring in the REPLACE trial prioritised hypoglycaemic reduction over a more indiscriminate approach to glucose control.(23)”
BackgroundMethodResultInfluentialKarter, A. J., Ackerson, L. M., Darbinian, J. A., D’Agostino, R. B., Ferrara, A., Liu, J., & Selby, J. V. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00742-2 · Cited by 595
Evans, J. M. M., Newton, R. W., Ruta, D. A., MacDonald, T. M., Stevenson, R. J., & Morris, A. D. (1999) · BMJ · doi:10.1136/bmj.319.7202.83 · Cited by 283
Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.015 · Cited by 239
Schütt, M., Kern, Krause, U., Busch, Dapp, A., Grziwotz, Mayer, I., Rosenbauer, Wagner, C., Zimmermann, et al. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-924152 · Cited by 218
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Zhu, H., Zhu, Y., & Leung, S.-W. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010524 · Cited by 84 · cited 1×
“In 2011, the UK NHS spent £158 million on SMBG, which accounted for 21% of prescription costs associated with diabetes.(13) DOI: https://doi.”
Background
Cited by
Recent advances in noninvasive flexible and wearable wireless biosensors
Salim, A., & Lim, S. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111422 · Cited by 153
Cowart, K., Updike, W., & Bullers, K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0345 · Cited by 36
Oyagüez, I., Merino-Torres, J. F., Brito, M., Bellido, V., Cardona-Hernandez, R., Gomez-Peralta, F., & Morales-Perez, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001330 · Cited by 33
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Metadata
- Authors
- Hellmund, R., Weitgasser, R., & Blissett, D.
- Venue
- European Endocrinology
- Publisher
- Touch Medical Media, Ltd.
- Published
- 2018
- Volume
- 14
- Issue
- 2
- Pages
- 86
- ISSN
- 1758-3772 (ISSN-L)
- OpenAlex
- W2891705875
- Cited by
- 17
- References
- 11
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.